Noxopharm Ltd. (AU:NOX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Noxopharm Limited has partnered with a seasoned Australian contract research organization to support its upcoming HERACLES clinical trial, focusing on areas such as drug safety and data management. This collaboration aims to ensure efficient trial execution and reliable data collection, marking a significant step forward for Noxopharm’s innovative cancer and inflammation treatments. The company is also progressing in selecting a Phase 1 unit to further advance the trial.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.